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Abstract
Background: The sensitivity of estrogen receptor-positive breast cancers to tamoxifen treatment varies considerably,
and the molecular mechanisms affecting the response rates are manifold. The human epidermal growth factor
receptor-related receptor HER2 is known to trigger intracellular signaling cascades that modulate the activity of
coregulators of the estrogen receptor which, in turn, reduces the cell sensitivity to tamoxifen treatment. However, the
impact of HER2-related receptor tyrosine kinases HER1, HER3, and, in particular, HER4 on endocrine treatment is largely
unknown.
Methods: Here, we retrospectively evaluated the importance of HER4 expression on the outcome of tamoxifen- and
aromatase inhibitor-treated estrogen receptor-positive breast cancer patients (n = 258). In addition, we experimentally
analyzed the efficiency of tamoxifen treatment as a function of HER4 co-expression in vitro.
Results: We found a significantly improved survival in tamoxifen-treated postmenopausal breast cancer patients in
the absence of HER4 compared with those with pronounced HER4 expression. In accordance with this finding, the
sensitivity to tamoxifen treatment of estrogen and HER4 receptor-positive ZR-75-1 breast cancer cells can be
significantly enhanced by HER4 knockdown.
Conclusion: We suggest an HER4/estrogen receptor interaction that impedes tamoxifen binding to the estrogen
receptor and reduces treatment efficiency. Whether the sensitivity to tamoxifen treatment can be enhanced by anti-
HER4 targeting needs to be prospectively evaluated.
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Background
Tamoxifen (TAM) treatment of hormone receptor-positive
breast cancer (BC) has proved to be a pioneering target-
specific therapy regimen [1] that was introduced more
than four decades ago [2]. The main indication for an ad-
juvant treatment of breast cancer with anti-estrogens is
the immunohistochemical identification of estrogen re-
ceptor (ER)-positive tumor cells that was suggested in
1987 [3] and has since evolved into a standardized
diagnostic procedure. TAM is being frequently applied in
the adjuvant (i.e., postsurgery) setting and in terms of re-
mission maintenance and according to the treatment
guidelines released by the American Society of Clinical
Oncology (ASCO) and the German Gynecologic-Oncol-
ogy Working Group (AGO) the application of the
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antiestrogen is conceived as a long-term (up to 10 years)
therapy [4, 5].
From a molecular point of view TAM has been devel-
oped to competitively bind ERs located in the cell nucleus
and thereby to competitively hamper the binding of estra-
diol. As a result, estradiol-specific (e.g., pro-proliferative)
effects are inhibited and tumor growth becomes retarded
or ideally even blocked [6, 7]. However, clinically
short- and long-term remissions achieved by endocrine
(TAM-based) treatment are often followed by the acquisi-
tion of resistance and, ultimately, disease relapse [8].
Treatment guidelines released by internationally recog-
nized expert organizations such as the Arbeitsgemeinschaft
der Wissenschaftlichen Medizinischen Fachgesellschaften
e.V. (Berlin, Germany), the National Comprehensive
Cancer Network NCCN™ (PA, USA), and the European
Society for Medical Oncology (ESMO; Viganello-Lugano,
Switzerland) all strongly recommend including an aroma-
tase inhibitor (AI) into the treatment regimens for
postmenopausal women (level of evidence 1b). AIs are de-
signed to inhibit the endogenous synthesis of the estrogen
receptor ligand estradiol and it has been demonstrated
that a sequential targeting of the endocrine receptor lig-
and system prolongs the period of remission by circum-
venting molecular mechanism that cause treatment
resistance [9, 10].
Both the ER and the human epidermal growth factor-re-
lated receptor 2 (HER2) represent dominant drivers for
the genesis and progression of BC [11]. The sensitivity to
target (i.e., ER and HER2 receptor) specific treatments is
affected by an extensive crosstalk of receptor-triggered
pathways [12]. Mechanistically, the HER2 receptor tyro-
sine kinase triggers a variety of downstream signaling
pathways, such as the RAF/RAS/MAPK cascade that re-
sults in phosphorylation of the ER and co-regulatory
molecules such as AIB1/Src-3 [12–17]. As a final conse-
quence, TAM binding to the ER is ineffective since it does
not weaken the transcriptional and pro-proliferative activ-
ity of the malignant cells. Nevertheless, HER2-induced
TAM resistance is clinically manageable by switching from
the anti-estrogen to an AI or by extending the treatment
by an anti-HER2 targeting [18–20]. Indeed, a number of
options to target alternate intracellular pathways are avail-
able to overcome HER2-induced TAM resistance [20].
However, HER2 does not work as a stand-alone receptor
but forms a functional unit with its relatives HER1, HER3,
and HER4. All HER receptors have prognostic impact on
BC disease [21–23]; however, the extent to which HER1,
HER3, and HER4 affect the sensitivity of ER-positive BC
cancers to TAM treatment is hardly known. Amongst the
four cognate receptor tyrosine kinases the HER4 receptor
might play an exceptional role in BC biology because it
has been associated either with a disadvantageous [24] or
with a favorable [21, 22] impact on the course and
outcome of disease. For instance, we previously reported a
positive impact of a gain of the HER4 gene locus on the
outcome of HER2-positive and trastuzumab-treated BC
patients [21, 23]. This finding has been later confirmed by
others [25]. By way of contrast, the presence of HER4 has
been associated with acquired resistance to HER2 inhibi-
tors such as lapatinib [26].
Here, we retrospectively analyzed the impact of HER4
expression on the course and outcome of ER-positive
breast cancer patients. To this end, we determined the
HER4 mRNA level of 258 ER-positive BC samples by
quantitative polymerase chain reaction (qPCR). Subco-
horts of pre- and postmenopausal patients were analyzed
independently and as a function of treatment with TAM
and AIs. These analyses were complemented by in vitro
TAM treatment of the strongly ER-positive ZR-75-1 BC
cell line. The impact of HER4 on the TAM treatment ef-
ficiency was evaluated by siRNA-based HER4 receptor
knockdown.
Compared with the cohort of BC patients without or
with only low HER4 expression we found poor overall sur-
vival of ER-positive and TAM-treated breast cancer
patients when the HER4 expression was high. This
phenomenon was pronounced and highly significant in
postmenopausal women. In contrast to the TAM-treated
patients, within the cohort of AI-treated women no im-
pact of HER4 expression on the course and outcome of
disease could be observed. In accordance with the analysis
on primary tumor samples, the sensitivity of ER- and
HER4-positive ZR-75-1 cells to TAM treatment could be
significantly enhanced by siRNA-based HER4 knockdown.
Taken together, the HER4 expression seems to impair the
efficiency of TAM but not AI treatment, even though the
predictive value of HER4 in ER-positive BC patients needs
to be prospectively evaluated.
Material and methods
ER-positive BC database
The pathological diagnostics were performed at the In-
stitute of Pathology at the University of Regensburg
(Regensburg, Germany). BC tissues were (immuno)his-
tochemically analyzed based on the estrogen/progester-
one receptor, Ki67, and Her2 receptor status and
grading and, if applicable, by fluorescence in situ
hybridization. Clinicopathological parameters were doc-
umented by the Institute of Pathology and the Breast
Cancer Center of the University Cancer Center Regens-
burg. Clinical follow-up was correlated with data from
the Tumor Center Regensburg, a population-based re-
gional cancer registry covering a population of more
than 2.2 million people including Upper Palatinate and
Lower Bavaria. The documentation comprises individ-
ual patient data, information on primary diagnosis,
treatment regimens, course of disease, and the complete
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follow-up. Table 1 lists the demographic and clinicopatho-
logical data of the patient collective n = 258 subjected to
this study.
Tissue embedding, processing, and immunohistochemistry
All specimens were acquired from the tissue archive of
the Institute of Pathology, University of Regensburg,
Germany. The embedding procedure was performed as
described elsewhere [27]. Immediately after surgery, the
breast tissues were transferred into the formalin fixative
(4% formaldehyde, 1% sodium phosphate; SG Planung,
Holzkirchen, Germany). The total fixation time was be-
tween 12 h (minimum) and 36 h (maximum). The speci-
mens were then subjected to automated dehydration and
paraffin immersion. Tissue dehydration was performed by
subjecting the tissues to a series of ascending ethanol con-
centrations (70% for 30 min, 70% for 60 min, 96% for
60 min, 96% for 50 min, 100% for 50 min, and 100% for
90 min), and was completed by incubation in 100% xylene
(2 × 50 min). Finally, the tissues were embedded in
paraffin with a Shandon Hypercenter XP (2 × 30 min;
2 × 60 min) and 1.5-μm paraffin sections were prepared
from the embedded tissue blocks. Specimens were depar-
affinized and pretreated by microwave heating for 30 min
at 320 W in 0.1 M citrate buffer adjusted to pH 7.3. The
immunostaining was automatically performed on a Ven-
tana Nexes autostainer (Ventana, Tucson, USA) by using
the streptavidin–biotin peroxidase complex method and
3,3’-diaminobenzidine (DAB) as a chromogen. The auto-
stainer was programmed based on the instructions given
by the OptiView DAB detection kit (Ventana). The mouse
monoclonal anti-ER antibody clone 6F11 (Leica Microsys-
tems GmbH, Novocastra, Wetzlar, Germany) was used at
a dilution of 1:35. The specimens were analyzed by con-
ventional bright field microscopy. ER positivity was rated
based on the recommendations given by Remmele and
Stegner [3].
RNA isolation, cDNA synthesis, and HER4-specific real-time
qPCR
Four different HER4 isoforms, namely JM-a/CYT1, JM-a/
CYT2, JM-b/CYT1, and JM-b/CYT2, resulting from dif-
ferential splicing have been described while the juxtamem-
brane (JM)-a variant represents the cleavable form [28]. It
has been shown that in BC only the cleavable JM-a iso-
forms are expressed [23, 29]. Accordingly, we used only
HER4/JM-a isoform-specific primers in this study. Base
sequences of primers and probes were as follows: forward
5’ CCA CCC ATC CCA TCC AAA-3′, reverse 5’ CCA
ATT ACT CCA GCT GCA ATC A-3′, Probe 5’
Fam-ATG GAC GGG CAATTC CAC TTTACC A-Dab-
cyl-3′. We have previously described the qPCR proced-
ure in detail [23]. Briefly, the miRNeasy RNA Isolation
Kit (Qiagen, Hilden, Germany) was used to extract
RNA from formalin-fixed and paraffin-embedded
tissue samples. For synthesis of cDNA, a template of
0.5 μg total RNA was used. According to the manu-
facturer’s instructions (Transcriptor First Strand
cDNA Synthesis Kit; Roche Diagnostics, Mannheim,
Germany), the reaction contains random hexamers
(Promega, Mannheim, Germany), reverse transcriptase
Table 1 Demographic data of 258 evaluated hormone
receptor-positive patients
Clinicopathological
parameter
Premenopausal
(n = 67)
Postmenopausal
(n = 191)
n % n %
Tumor stage
I 32 48 111 58
II 28 42 67 35
III 4 6 8 4
IV 0 0 0 0
Unknown 3 4 5 3
Subtype
Invasive ductal 56 84 151 79
Invasive lobular 7 10 24 13
Others 4 6 16 8
Grading
1 5 7 25 13
2 44 66 110 58
3 17 25 52 27
Unknown 1 1 4 2
Lymph node status
0 30 45 116 61
1 19 28 52 27
2 10 15 13 7
3 6 9 6 3
Unknown 2 3 4 2
Endocrine treatment
Tamoxifen 43 64 66 35
Aromatase inhibitor 24 36 125 65
Surgery
Mastectomy 27 40 51 27
Breast-conserving therapy 40 60 140 73
Radiation
Yes 50 75 151 79
No 7 10 23 12
Unknown 10 15 17 9
Cytotoxicity treatment
Yes 56 84 85 44
No 1 1 3 2
Unknown 10 15 103 54
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(Promega), dNTP-mixture, and RNAse inhibitor. All
reactions were performed in duplicate in the presence
and absence of reverse transcriptase. Real-time PCR
was performed using fluorescent oligonucleotide
LC480 hybridization probes (Metabion, Martinsried,
Germany). A calibration standard as well as probes and
primers annealing to mRNA of β-actin were used as
internal reference and for comparison of successive
experiments. PCR was carried out in a final volume of
10 μl containing 2.5 μl cDNA template (1:5 attenuation),
5 μl LC480 Probes Master (Roche), 1 μl probe, and 1.5 μl
primers (0.75 μl primer β-actin, 0.75 μl primer target).
Probes were labeled with fluorescent reporter dyes FAM
(Her4 isoform probes) or LC Red (β-actin probes).
Thermal cycling started with the pre-incubation at 95 °C
for 10 min. Then amplification was carried out by running
45 cycles, initiated with 30 s at 60 °C followed by 15 s at
95 °C on a LC480 device.
ZR-75-1 cell line incubation, TAM treatment, and siRNA-based
HER4 knockdown
The ZR-75-1 BC cell line was purchased from the
American Type Culture Collection (ATCC number
CRL-1500, Manassas, VA, USA). For this study, the cell
line was authenticated by the Leibniz-Institute “German
Collection of Microorganisms and Cell Culture” GmbH
(DSMZ, Braunschweig, Germany).
ZR-75-1 cells were cultured in Roswell Park Memorial
Institute 1640 medium (RPMI-1640) supplemented with
5% fetal calf serum (FCS) (both from PAN Biotech,
Aidenbach, Germany). Cells were commonly seeded at
densities of 2 × 105 cells per T75 tissue flask (Greiner
Bio-One, Frickenhausen, Germany) and were incubated
in a humidified atmosphere containing 5% CO2 at 37 °C.
Culture medium was refreshed every 2 days. For harvest-
ing, cells were washed with phosphate-buffered saline
(PBS; pH 7.4, Biochrom, Berlin, Germany) and were de-
tached from culture flasks by incubating for 3 min at
37 °C in a PBS solution supplemented with 0.05% trypsin
and 0.02% ethylenediaminetetraacetic acid.
For the siRNA-mediated HER4 downregulation, 5 × 105
ZR-75-1 cells were seeded in a T25 tissue flask in
RPMI-1640 medium supplemented with 5% FCS on day 0.
The next day, the medium was removed and 2.5, 2.3, and
2.1 ml (untreated sample/DharmaFECT-treated sample/
siRNA sample) fresh RPMI/1% FCS was added, respect-
ively. The transfection mix was prepared by incorporation
of 10 μl DharmaFECT (Dharmacon, Lafayette, CO, USA)
with 190 μl Opti-MEM (Invitrogen, Karlsruhe, Germany)
in tube 1 and 12.5 μl of 10 μM anti-HER4 siRNA
(L-003128-00-0005 ON-TARGETplus SMARTpool Hu-
man ERBB4 2066, Dharmacon) and 187.5 μl Opti-MEM
in tube 2. For control purposes we exposed the cells to
non-targeting siRNA (D-001810-10-05 ON-TARGETplus
Non-targeting Pool; Horizon Discovery Ltd., CA, USA)
which is expected to cause no effect on receptor expres-
sion and cell proliferation. After 5 min incubation at room
temperature the contents of tube 1 and tube 2 were
pooled and subsequently thoroughly mixed. After a fur-
ther incubation step of 20 min at room temperature the
400-μl transfection mix was added per flask to give a final
siRNA concentration of 50 nM. From day 2 on, the cells
were treated with 5 μM TAM for 96 h (Sigma-Aldrich
Chemie GmbH, Deisenhofen, Germany).
Western blotting
Treated and untreated ZR-75-1 cells were lysed for total
protein analysis in cell-lysis buffer (Cell Signaling,
Danvers, MA, USA) supplemented with Halt™ Protease
and Phosphatase Inhibitor Cocktail (Thermo Fisher Scien-
tific, Bremen, Germany). After calculating the protein
concentration with the Pierce BCA protein assay kit
(ThermoFisher), 25 μg total protein per lane were
separated in 7.5% SDS-PAGE under reducing conditions
(mercaptoethanol) and blotted onto polyvinylidene
difluoride (PVDF) membranes. Membranes were blocked
with Tris-buffered saline supplemented with 5% low-fat
milk and 2% Tween for 2 h and then incubated overnight
at 4 °C using the following primary antibodies: rabbit
anti-human HER1 (D38B1; 1:1000), rabbit anti-human
HER2 (29D8; 1:4000), rabbit anti-human HER3 (D22C5;
1:200), rabbit anti-human HER4/ErbB4 (111B2; 1:1000)
(all from Cell Signaling Technology), rabbit anti-human
β-actin (A2066; 1:5000, Sigma-Aldrich Chemie GmbH),
and mouse anti-estrogen receptor (NCL-L-ER-6F11;
1:500, Leica Microsystems). The next day, after washing
the membrane, incubation with secondary antibodies
(goat anti-rabbit 7074 HRP-conjugated and horse
anti-mouse (7076) HRP-conjugated; both 1:2000, and both
from Cell Signaling Technology) was performed for 1 h at
room temperature. The blots were visualized using the
chemiluminescent Western blotting detection system (GE
Healthcare, Amersham, UK) and analyzed by ImageQuant
LAS 4000 mini-imager (GE Healthcare).
Proliferation assessment by flow cytometry
BrdU/Hoechst quenching measurements (i.e., the assess-
ment of G0-phase fraction) were performed as described
previously [30]. This approach is based on continuous
labeling of cells in vitro with BrdU which is incorporated
into the DNA instead of thymidine during the cell cycle
S phase. BrdU incorporation results in quenching of
Hoechst 33258 but not of propidium iodide upon DNA
double staining. Thus, actively proliferating cells and
quiescent (i.e., G0 phase) cells can be differentiated and
separately quantified. For flow cytometric cell analyses,
5 × 105 cells were seeded on day 0 into T25 culture
flasks and were incubated for 7 days. At day 4, 120 μM
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BrdU was added to the culture flasks and cells were in-
cubated in the presence of BrdU for an additional 72 h.
To minimize potential disturbance in the nucleotide
pathway due to BrdU treatment, the medium was also
supplemented with half-equimolar 2’deoxycytidine. After
detachment the cells were stored at −20 °C at a concen-
tration of 106 cells/ml in freezing medium (RPMI-1640
medium + 10% FCS + 10% dimethyl sulfoxide (DMSO))
until flow cytometric analysis. For cell staining, thawed
cells were washed twice with 2 ml ice-cold
DNA-staining buffer (100 mM Tris-HCl, pH 7.4,
154 mM NaCl, 1 mM CaCl2, 0.5 mM MgCl2, 0.1% IGEP
AL CA-630 (Nonylphenylpolyethylenglycol), 0.2% bovine
serum albumin (BSA)); 5 × 105 cells were resuspended in
1 ml buffer supplemented with 40 g/ml (2–4 units/ml)
RNase and 1.2 μg/ml Hoechst 33258 (Sigma-Aldrich)
and incubated for 15 min at 37 °C. Cellular DNA con-
tent was stained with propidium iodide (1.5 μg/ml) for
15 min on ice. Samples were passed through a 70-μm
nylon mesh to remove cell aggregates prior to flow cyto-
metric analysis. Flow cytometric measurements were
performed on a FACSCanto II flow cytometer (BD Bio-
sciences, San Jose, CA) equipped with a blue (488 nm),
red (633 nm), and violet (405 nm) laser and a standard
optical configuration. Sample measurements and data
analysis were performed with FACSDiva Software v7.0
(BD Biosciences), and 50,000 events/sample were col-
lected. As described previously in detail, the G0 cell frac-
tion was calculated by taking into account the fraction
of cells that had divided once, twice, or three times
within the period of observation [31].
Statistical analyses
Overall survival (OS) was calculated from the date of
diagnosis to the date of death of any cause. Patients who
survived were classified as censored cases at the latest
date they were confirmed to be alive. Disease-free sur-
vival (DFS) was calculated as the period of time after
(successful) primary treatment without any evidence of
cancer-related signs, symptoms, or death. Patients with-
out any cancerous disease and being alive were classified
as censored cases at the latest date they were confirmed
to be disease free and alive. Maximum follow-up time
was set to 10 years. Patients with a longer follow-up
were classified as censored cases after 10 years. The
impact of HER4 expression on DFS and OS was calcu-
lated for all patients and subcohorts (i.e., pre- versus
postmenopausal, TAM- versus AI-treated patients).
Survival curves were estimated using the Kaplan–Meier
method and hazard ratios (HRs) and corresponding 95%
confidence intervals (Cis) were calculated by Cox pro-
portional hazards regression models for the univariate as
well as for the multivariable models. An optimal cut-off
for HER4 values for predicting OS and DFS was esti-
mated based on log-rank statistics. All reported p values
were two-sided. A p value lower than 0.05 was consid-
ered to indicate a significant difference. All statistical
analyses were performed using R version 3.3.3 (The R
Foundation for Statistical Computing) or GraphPad
Prism (Ver. 6, GraphPad Software, La Jolla, CA, USA).
Results
Considering the entire collective HER4 expression has no
significant impact on the outcome of disease
No correlation of HER4 expression (continuously or di-
chotomized) with the DFS or the OS could be found when
all patients (i.e., without regard to the treatment regimen
and age) were included into the analysis (Table 2).
HER4 expression has a significant impact on the outcome
of TAM-treated but not on the outcome of AI-treated
patients
When considering TAM-treated patients, a significant im-
pact of HER4 expression on the OS was found (HR = 1.28
HER4 continuous; HR 3.22, HER4 ≥ 1, respectively; Table
3). Further analyses identified a better cut-off for the
HER4 expression of the TAM-treated group, with HER4 <
1 (HER4-negative) versus HER4 ≥ 1 (HER4-positive). In
contrast to the TAM-treated cohort, in the AI-treated sub-
population no correlation of HER4 expression to the OS
(HR = 0.86 and 0.68, respectively) or DFS (HR = 0.85 and
0.72, respectively) was seen (Table 3).
Further stratification of the TAM-treated group based
on the pre- and postmenopausal status (< 46 years vs. ≥
46 years) revealed that HER4 expression had a signifi-
cant impact on the OS (HR =1.43, HER4 continuous;
HR =4.98, HER4 ≥ 1) and DFS (HR = 1.81, HER4 con-
tinuous) only in postmenopausal but not in premeno-
pausal women (Table 4).
Table 2 Impact of HER4 expression on the overall survival (OS) and disease-free survival (DFS) in all patients (independent of menopausal
status and treatment)
Predictor OS DFS
HR 95% CI p value HR 95% CI p value
HER4 continuous 1.08 0.87 1.35 0.474 1.00 0.80 1.25 0.993
HER4-positive (ref. no HER4 expression) 0.90 0.49 1.66 0.736 0.91 0.54 1.55 0.733
CI confidence interval, HR hazard ratio
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Kaplan–Meier survival curves confirmed that the OS of
TAM-treated patients was significantly (p = 0.0167) im-
proved in HER4-negative BC patients, which was inde-
pendent of their menopausal status (Fig. 1, left column).
No significant difference (p = 0.433) was detectable with
respect to the DFS (Fig. 1, right column). Classification by
age revealed no significant differences for DFS (p = 0.37)
or OS (p = 0.652) in TAM-treated premenopausal
(< 46 years of age) patients (Fig. 1, middle row). However,
the OS (p = 0.0087) was significantly impaired in
postmenopausal HER4-positive patients (≥ 46 years of age;
Fig. 1, bottom row). The DFS of postmenopausal and
TAM-treated women tends to be significantly better in
case of HER4-negative BC compared with HER4-positive
BC (p = 0.0477; Fig. 1, bottom row).
Patients treated with AIs did not display any significant
HER4 dependency with respect to OS and DFS, neither in
pre- nor in postmenopausal patients (all p values greater
than 0.05, Fig. 2). However, a trend towards an improved
(rather than to an impaired) course and outcome of dis-
ease in HER4-positive patients compared with women
with HER4-negative tumors became apparent.
To assess if HER4 is an independent predictor for OS
and DFS within the TAM-treated postmenopausal women,
a multivariable Cox regression model was applied (Table 5).
Due to the limited number of events only two further cov-
ariables were added to the model. Based on clinical rele-
vance and statistical significance, patient age and tumor
staging (pT) were selected. In the adjusted models, HER4
as a continuous variable remains a significant predictor for
both OS (p = 0.035, HER4 continuous) and DFS (p = 0.003,
HER4 continuous).
HER4 downregulation enhanced efficiency of TAM
treatment in vitro
HER4 knockdown in ER-positive ZR-75-1 breast cancer
cells resulted in about 90% reduced HER4 protein levels
(Fig. 3a). Off-target effects on the other members of the
HER receptor family (i.e., HER1, HER2, and HER3)
could be excluded (Fig. 3b–d). The unaffected ER ex-
pression in ZR-75-1 cells is exemplarily shown in Fig. 4a.
BrdU/Hoechst quenching assay was applied to quantify
the different TAM efficiencies in wild-type (WT) and
HER4 knockdown cells. This technique allows the quan-
titative assessment of proliferating and resting cells. Cells
which stop proliferation are considered to become qui-
escent and to enter the G0/G1 resting phase. Repeated
measurements revealed a significantly increased fraction
of G0-phase cells in the presence of TAM treatment
compared with untreated cells (Fig. 4b). This observa-
tion applies to both WT (p < 0.001) cells and cells
treated with non-targeting siRNA (p < 0.001). However,
TAM treatment efficiency is significantly enhanced in
ZR-75-1 cells upon HER4 receptor knockdown com-
pared with ZR-75-1 cells with regular HER4 expression
(on average 19% versus 47.0%, p < 0.0001). Flow cyto-
metric example measurements are shown in Fig. 4c. An
increased fraction of G0/G1 resting cells upon TAM
Table 3 Impact of HER4 expression on the overall survival (OS) and disease-free survival (DFS) in patient subcohorts stratified by
treatment (TAM or AI)
Subgroup Predictor OS DFS
HR 95% CI p value HR 95% CI p value
TAM treated HER4 continuous 1.28 1.01 1.62 0.040 1.16 0.89 1.52 0.270
HER4 expression (ref. no HER4 expression) 1.63 0.52 5.06 0.399 1.23 0.54 2.84 0.622
HER4≥ 1 (ref. HER4 < 1) 3.22 1.17 8.86 0.024 1.36 0.63 2.97 0.436
Al treated HER4 continuous 0.86 0.60 1.22 0.393 0.85 0.61 1.18 0.338
HER4 expression (ref. no HER4 expression) 0.68 0.31 1.50 0.339 0.72 0.36 1.44 0.352
Significant values are shows in bold typeface
AI aromatase inhibitor, CI confidence interval, HR hazard ratio, TAM tamoxifen
Table 4 Impact of HER4 expression on the overall survival (OS) and disease-free survival (DFS) in tamoxifen-treated patients stratified
by menopausal status
Strata Predictor OS DFS
HR 95% CI p value HR 95% CI p value
Premenopausal (< 46 years) HER4 continuous 1.06 0.59 1.89 0.845 0.77 0.43 1.38 0.380
HER4≥ 1 (ref. HER4 < 1) 1.51 0.25 9.01 0.655 0.56 0.15 2.03 0.377
Postmenopausal (≥ 46 years HER4 continuous 1.43 1.09 1.86 0.009 1.81 1.25 2.63 0.002
HER4≥ 1 (ref. HER4 < 1) 4.98 1.32 18.80 0.018 2.94 0.96 9.00 0.059
Significant values are shows in bold typeface
CI confidence interval, HR hazard ratio
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Fig. 1 Disease outcome of TAM-treated ER-positive breast cancer patients. OS and DFS are displayed for all patients (top row), only premenopausal
(< 46 years; middle row), and only postmenopausal (≥ 46 years, bottom row) breast cancer patients treated with TAM. The p values were calculated
using the log-rank test (Mantel–Cox) and are indicated in each graph
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Fig. 2 Disease outcome of AI-treated ER-positive breast cancer patients. OS and DFS are displayed for all patients (top row), premenopausal
(< 46 years; middle row), and postmenopausal (≥ 46 years, bottom row) breast cancer patients treated with AI. The p values were calculated using
the log-rank test (Mantel–Cox) and are indicated in each graph
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treatment was measured in ZR-75-1 wild-type cells (6%
in untreated vs. 19% in treated cells). This effect was sig-
nificantly enhanced upon HER4 knockdown (9.2% in un-
treated vs. 47% in treated cells; p = 0.0001). The
quiescent cells were not able to proceed with cycling
within the period of treatment/observation and are
blocked in G0/G1 of the first cycle.
Discussion
For about four decades, TAM (which binds to and antago-
nizes the ER) has been the mainstay of endocrine therapy
in both early and advanced breast cancer patients.
Although the hormone treatment has brought significant
benefit to hormone receptor-positive BC patients, up to
50% of patients with advanced disease do not respond to
first-line treatment but show de novo resistance. Another
significant cohort of advanced BC patients in the adjuvant
setting acquire resistance while treated with TAM and
later on develop tumor relapse [20]. Mechanisms that
contribute to or directly cause resistance to the TAM
treatment are manifold [19], although receptor tyrosine ki-
nases (e.g., HER2) are frequently involved. In order to
evade TAM resistance, AIs that inhibit the endogenous
synthesis of the native ER activating ligand estrogen can
be administered sequentially with TAM [20] or as
first-line treatment, especially for postmenopausal women.
Here, we retrospectively analyzed the impact of HER4 on
the course and outcome of TAM- or AI-treated patients
with ER-positive BC. In addition, we evaluated the TAM
treatment efficiency of ER-positive ZR-75-1 BC cells in
vitro as a function of HER4 receptor expression.
We found a significant unfavorable effect of HER4 in
patients treated with TAM but not in women treated
with AIs. A detailed analysis of sample subcohorts fur-
ther disclosed a strong and significant impact in post-
menopausal but not in premenopausal patients. In vitro
analyses revealed that the proliferation of markedly
ER-positive ZR-75-1 cells was inhibited when exposed to
TAM. However, the treatment efficiency was signifi-
cantly enhanced upon siRNA-based HER4 knockdown.
Apparently, HER4 impedes the efficiency of TAM but
not AI treatments. The unfavorable impact of HER4 on
the outcome of TAM- but not AI-treated patients suggests
a direct interaction of HER4 with the ER. A possible ex-
planation is the ER-stimulating activity of the intracellular
HER4 domain when translocated into the tumor cell
nucleus [32, 33] (Fig. 5). A nuclear localization can be ex-
plained by a two-step intramembrane proteolysis of the
HER4 receptor [34]. First, a metalloproteinase called
tumor necrosis factor α converting enzyme (TACE) can
cleave and release the HER4 ectodomain. Second, this
proteolysis can be followed by an intracellular cleavage
performed by γ-secretase that releases an intracellular do-
main (4ICD) into inner cell compartments. Depending
upon specific molecular interactions [35], the 4ICD either
translocates to the nucleus or remains in the cytosol
where mitochondrial accumulation has been observed. As
a protein with pronounced BCL-2 homology-3, the 4ICD
can interact with pro-apoptotic molecules located in the
mitochondrial membrane and initiate apoptotic cell death
by cytochrome-c release [33, 36]. In contrast, when trans-
ferred into the nucleus, 4ICD can work as a co-activator
of the estrogen receptor and - in the presence of exogen-
ous estrogen - contribute to enhanced (tumor) cell growth
[32] and thereby possibly account for an unfavorable dis-
ease course [37, 38]. The subcellular localization might
also be determined by a differential expression of intracel-
lular isoform domains [33, 34, 38–40]. Even if only the
juxtamembranous cleavable isoform JM-a (but never
JM-b) is expressed in BC [28, 29, 39, 40], two different
cytoplasmatic domains (i.e., CYT1 and CYT2) potentially
occur also in the sample cohort of this study. Notably,
CYT1 and CYT2 domains have been shown to interact
with different intracellular molecules that are involved in
cell compartment (cytoplasm vs. nucleus)-specific 4ICD
routing [41]. In this study, we did not differentiate the two
Table 5 Multivariable Cox regression analysis of tamoxifen-treated postmenopausal women on the overall survival (OS) and disease-
free survival (DFS) including HER4, patient age, and tumor stage
OS (n = 64, events = 12) DFS (n = 64, events = 12)
HR 95% CI p value HR 95% CI p value
Model 1
HER4 continuous 1.41 1.02 1.95 0.035 2.34 1.34 4.06 0.003
Age 1.14 1.07 1.21 < 0.001 1.11 1.05 1.18 < 0.001
pT stage (ref. pT1) 4.98 1.11 22.37 0.036 4.01 1.10 14.64 0.035
Model 2
HER4≥ 1 (ref. HER4 < 1) 3.89 0.92 16.37 0.064 2.38 0.71 8.00 0.161
Age 1.12 1.05 1.18 < 0.001 1.09 1.04 1.15 0.001
pT2 or higher (ref. pT1) 6.68 1.60 27.93 0.009 3.80 1.13 12.80 0.031
Significant values that refer to HER4 are shown in bold typeface
CI confidence interval, HR hazard ratio, pT tumor stage
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HER4-specific intracellular domains; however, a preferred
routing to the cell nucleus might have contributed to the
unfavorable impact of HER4 expression on ER-positive/
TAM-treated patients. The assumed mechanisms of ER
action in the presence and absence of HER4/4ICD are il-
lustrated in Fig. 5. The two-step proteolytic activation of
HER4 by TACE and y-secretase [29] causes the release of
4ICD into inner cell compartments. If translocated into
the nucleus, 4ICD, as an ER co-activator, enhances the
pro-proliferative effect of estrogen. Within an autoloop,
4ICD also enhances the transcription of HER4 itself. In
contrast, HER4 receptor knockdown eliminates the
co-stimulatory activity of 4ICD. As a consequence, appro-
priately dosed TAM can competitively replace the estro-
gen and binds to the ER. As a result, pro-proliferative
activity of the ER is inhibited.
We previously associated the presence of HER4 with
an improved outcome in BC patients [21, 22]. In con-
trast to former studies, however, we herein explicitly ex-
plored hormone receptor (i.e., ER)-positive BCs, and
HER4 might mediate different effects in different BC
subtypes. Indeed, it has been experimentally shown that
TAM disrupts an estrogen-driven interaction between
ER and 4ICD while promoting mitochondrial accumula-
tion of the 4ICD/BH3-only protein [36]. Accordingly, it
seems plausible that a 4ICD/ER interaction impairs
TAM binding and reduces treatment efficiency both in
vivo and in vitro. The increased sensitivity of ZR-75-1
cells to TAM treatment on HER4 knockdown supports
the assumption that the HER4/4ICD directly interferes
with the TAM-ER binding. Nevertheless, other mecha-
nisms that underlie HER4/4ICD-mediated reduced TAM
efficiency cannot be excluded.
An ER/4ICD interaction would explain the reduced effi-
ciency of TAM treatment in the presence of HER4/4ICD
and the improved outcome of patients with ER+/HER4low
tumors compared with patients who suffer from ER+/
HER4high tumors. Moreover, it would also be compatible
with the lack of impact of HER4 in AI-treated patients.
Since AIs do not affect the ER function but inhibit the
synthesis of the ER ligand, a direct ER/4ICD interaction
would neither be affected by an administration of AIs, nor
would the AI treatment efficiency be affected by the pres-
ence of HER4 (i.e., the 4ICD/ER crosstalk).
In AI-treated patients we found a trend towards an
improved (rather than to an impaired) course and
outcome of disease in HER4-positive patients. Notably,
this trend is in reverse to the negative significant effect
of HER4 in TAM-treated patients and might be
explained by the absence (or reduced systemic level) of
estrogen in AI-treated women. A reduced presence of
ER might entail a pronounced accumulation of 4ICD in
the cytoplasm where it induces a rather tumor-
suppressive effect by a pro-apoptotic (i.e., favorable)
activity [33, 42, 43].
Notably, stratified analyses revealed a significant im-
pact of HER4 in ER-positive and TAM-treated BC pa-
tients for postmenopausal but not for premenopausal
women. This finding might to some extent be explained
by different age-related estrogen synthesis. In premeno-
pausal women estrogens are mainly synthesized in the
ovaries, whereas in postmenopausal women the final
synthesis occurs in peripheral tissues such as mesenchy-
mal cells from adipose tissue (including the breast),
bones, muscle, or brain. Important for the final synthesis
is aromatase which can be detected in non-malignant
Fig. 3 Reduced HER4 protein expression in siRNA-treated ZR-75-1
breast cancer cell line. Western blot analyses of HER4 (a), HER1 (b),
HER2 (c), and HER3 (d) are shown for cell lysates gained from untreated
ZR-75-1 control cells (–), cells treated with non-targeting siRNA (NT),
and ZR-75-1 cells treated with targeting anti HER4/siRNA (T). One
representative blot is shown, respectively, and repeated experiments
(n = 3) are summarized in the corresponding bar charts. P values are
calculated using one-way ANOVA and Tukey’s multiple comparisons
test (****p < 0.0001). WT wild-type
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adipose tissue but also in breast tumors [43]. Indeed, the
estrogen level in the peripheral blood in premenopausal
women is higher compared with postmenopausal women
[44]. However, the tissue concentration of estrogen
sulfate, sulfatase, and aromatase activities was signifi-
cantly higher in postmenopausal women [45]. In
addition, significantly higher estrogen concentrations
could be even found in malignant versus normal tissues
Fig. 4 HER4 siRNA knockdown enhances the tamoxifen (TAM)-induced G0/G1 fraction. a The expression of the estrogen receptor (ER) in ZR-75-1
wild-type cells is exemplarily shown by Western blot. St. represents the protein standard and – and + refer to the samples without and with anti-
HER4 siRNA treatment, respectively. The molecular weight of the ER is about 66 kDa. The ER expression was not affected by an anti-HER4 siRNA
treatment. b Percentage of G0/G1 phase (quiescent) cells in wild-type (WT), non-targeting siRNA control, and HER4 knockdown ZR-75-1 BC cells
with or without TAM treatment is shown (n = 3; mean ± SD). P values are calculated using two-way ANOVA and Sidak’s multiple comparisons test
(***p < 0.001; ****p < 0.0001). c Example density plots from flow cytometric analyses (BrdU/Hoechst quenching assay) are displayed. The size of
the G0/G1 fraction of the first cell cycle is indicated, respectively
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[46, 47]. Moreover, the ER level affects the estradiol
levels found in tissues and can cause a significant (up to
8-fold) increased estradiol level in ER-positive tumor
tissue [48]. Hence, the local estrogen synthesis is
increased especially in ER-positive tumors. Provided that
the anti-estrogen TAM is mainly effective in the (local)
presence of estradiol it appears plausible that an
ER-TAM-HER4/4ICD interaction is relevant in particular
in postmenopausal women. Thus, a reduced efficiency of
TAM treatment in elderly BC patients becomes mainly
apparent in the presence of HER4. This finding might to
some extent also be due to the larger sample cohort of
Fig. 5 Suggested mechanism of estrogen receptor (ER) action in the presence and absence of HER4. a HER4 can be processed by a two-step
proteolytic activation. First tumor necrosis factor α converting enzyme (TACE) cleaves the extracellular domain, and subsequently y-secretase
cleaves the intracellular domain of HER4 (4ICD) which is released into inner cell compartments. If translocated into the nucleus, 4ICD as an ER
co-activator enhances the pro-proliferative effects of estrogen. Within an autoloop, 4ICD also enhances the transcription of HER4 itself. b HER4
receptor knockdown eliminates the co-stimulatory activity of 4ICD. As a consequence, appropriately dosed tamoxifen (TAM) can competitively
replace the estrogen and binds to the ER. As a result, pro-proliferative activity of the ER is inhibited
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postmenopausal women compared with the number
premenopausal patients.
The finding of impaired TAM treatment efficiency in
the presence of HER4 might have clinical implications
and might promote alternate therapeutic strategies, par-
ticularly in postmenopausal women. Analogously to ER
and HER2 testing, the BC diagnostics could be extended
by the evaluation of HER4 expression. If the TAM treat-
ment efficiency is low in an ER/HER4 double-positive
tumor one might preferably switch to an AI treatment.
Alternatively, combined ER/HER4 receptor targeting
might restore TAM sensitivity or even enhance the endo-
crine treatment efficiency. Anti-HER4 targeting can be
performed based on different strategies. On the one hand,
an HER4 JM-a type-specific anti-HER4 monoclonal anti-
body, called Ab1479, has been reported to block HER4
cleavage in BC cells and to suppress BC cell growth in
vivo and in vitro [34, 49]. A systematic clinical trial on ER/
HER4 double-positive BC could potentially result in clin-
ical approval of Ab1479 for the treatment of this BC en-
tity. Alternatively, pan-HER-receptor inhibitors, e.g.,
afatinib or neratinib, could be administered in combin-
ation with an anti-estrogen [50, 51]. By using the latter
strategy not only HER4 but also the potentially expressed
HER2 receptor, which is frequently involved in TAM
resistance, would be targeted at the same time. After all,
in addition to immunohistochemistry and in-situ
hybridization, a number of quantitative and multiplexed
HER1–4 analytics became available to quantify HER1–4
receptors and categorize the patients for individualized
treatments [21, 52, 53]. However, all the suggested strat-
egies require prospective clinical testing and approval in
advance.
Conclusion
Here we provide evidence for the HER4 receptor as a
new predictive marker for the sensitivity of ER-positive
BC to TAM treatment, especially in postmenopausal pa-
tients. Dual ER/HER4 targeting might improve the treat-
ment efficiency of hormone receptor-positive BC but
needs to be prospectively evaluated in an appropriate
preclinical and clinical setting.
Abbreviations
4ICD: Intracellular domain of HER4; AI: Aromatase inhibitor; BC: Breast cancer;
CI: Confidence interval; CYT: Cytoplasmatic domain; DFS: Disease-free survival;
ER: Estrogen receptor; HER: Human epidermal growth factor-related receptor;
HR: Hazard ratio; JM: Juxtamembrane; OS: Overall survival; TACE: Tumor necrosis
factor α converting enzyme; TAM: Tamoxifen; WT: Wild-type
Acknowledgements
We thank Dr. Florian Weber (Institute of Pathology, University of Regensburg,
Germany) for the careful and professional inspection of the histological BC
specimens. We would like to thank Prof. Christoph Klein (Dept. of Experimental
Medicine and Therapy Research, University of Regensburg) for providing access
to the LC480 technology. The authors are also grateful to Gerhard Piendl and
Veruschka Albert (both Department of Gynecology, University of Regensburg)
who supported the project with their perfect technical assistance.
Funding
This work has been funded by the German research foundation (Deutsche
Forschungsgemeinschaft), project number BR1873/9–1.
Availability of data and materials
All data generated and/or analyzed during this study are included in this
published article.
Authors’ contributions
AKW provided analysis of the ex-vivo and in vitro data, and was a co-author
of the manuscript. DC performed the in vitro experiments. SB co-authored the
manuscript. FZ provided statistical analyses. MKS provided documentation
and processing of clinicopathological data. SDD assisted vitally in the in vitro
experiments. OO co-authored the manuscript. GB provided study design and
supervision, wrote the manuscript, and was principle investigator. All authors
read and approved the final manuscript.
Ethics approval and consent to participate
In compliance with the Helsinki Declaration and in accord with the statements
given by the local ethics committee of the University of Regensburg, ethics
approval and informed consent was not required for this study.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Author details
1Clinic of Gynecology and Obstetrics, University Medical Center Regensburg,
Regensburg, Germany. 2Department of Nephrology, University Hospital
Regensburg, Regensburg, Germany. 3Tumor Center Regensburg, University of
Regensburg, Regensburg, Germany. 4Center for Clinical Studies, University
Hospital Regensburg, Regensburg, Germany.
Received: 17 April 2018 Accepted: 1 November 2018
References
1. Jordan VC. Tamoxifen as the first targeted long-term adjuvant therapy for
breast cancer. Endocr Relat Cancer. 2014;21:R235–46.
2. Lippman ME, Bolan G. Oestrogen-responsive human breast cancer in long
term tissue culture. Nature. 1975;256:592–3.
3. Remmele W, Stegner HE. Vorschlag zur einheitlichen Definition eines
Immunreaktiven Score (IRS) für den immunhistochemischen
Ostrogenrezeptor-Nachweis (ER-ICA) im Mammakarzinomgewebe.
Pathologe. 1987;8:138–40.
4. Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE,
Giordano SH, Hudis CA, Rowden D, Solky AJ, Stearns V, Winer EP, Griggs JJ.
Adjuvant endocrine therapy for women with hormone receptor-positive
breast cancer: American Society of Clinical Oncology clinical practice
guideline focused update. J Clin Oncol. 2014;32:2255–69.
5. Thomssen C, Augustin D, Ettl J, Haidinger R, Lück H-J, Lüftner D, Marmé F,
Marschner N, Müller L, Overkamp F, Ruckhäberle E, Thill M, Untch M,
Wuerstlein R, Harbeck N. ABC3 Consensus: assessment by a German group
of experts. Breast Care (Basel, Switzerland). 2016;11:61–70.
6. Allred DC, Anderson SJ, Paik S, Wickerham DL, Nagtegaal ID, Swain SM,
Mamounas EP, Julian TB, Geyer CE, Costantino JP, Land SR, Wolmark N.
Adjuvant tamoxifen reduces subsequent breast cancer in women with
estrogen receptor-positive ductal carcinoma in situ: a study based on
NSABP protocol B-24. J Clin Oncol. 2012;30:1268–73.
7. Bartlett JMS, Brookes CL, Robson T, van de Velde CJH, Billingham LJ, Campbell
FM, Grant M, Hasenburg A, Hille ETM, Kay C, Kieback DG, Putter H, Markopoulos
C, Kranenbarg EM-K, Mallon EA, Dirix L, Seynaeve C, Rea D. Estrogen receptor
and progesterone receptor as predictive biomarkers of response to endocrine
therapy: a prospectively powered pathology study in the Tamoxifen and
Exemestane Adjuvant Multinational trial. J Clin Oncol. 2011;29:1531–8.
Wege et al. Breast Cancer Research          (2018) 20:139 Page 13 of 15
8. Viedma-Rodríguez R, Baiza-Gutman L, Salamanca-Gómez F, Diaz-Zaragoza
M, Martínez-Hernández G, Ruiz Esparza-Garrido R, Velázquez-Flores MA,
Arenas-Aranda D. Mechanisms associated with resistance to tamoxifen in
estrogen receptor-positive breast cancer (review). Oncol Rep. 2014;32:3–15.
9. Peddi PF. Hormone receptor positive breast cancer: state of the art. Curr
Opin Obstet Gynecol. 2018;30:51–4.
10. Tremont A, Lu J, Cole JT. Endocrine therapy for early breast cancer: updated
review. Ochsner J. 2017;17:405–11.
11. Alqaisi A, Chen L, Romond E, Chambers M, Stevens M, Pasley G, Awasthi M,
Massarweh S. Impact of estrogen receptor (ER) and human epidermal
growth factor receptor-2 (HER2) co-expression on breast cancer disease
characteristics: implications for tumor biology and research. Breast Cancer
Res Treat. 2014;148:437–44.
12. Giuliano M, Trivedi MV, Schiff R. Bidirectional crosstalk between the
estrogen receptor and human epidermal growth factor receptor 2 signaling
pathways in breast cancer: molecular basis and clinical implications. Breast
Care (Basel, Switzerland). 2013;8:256–62.
13. Osborne CK, Schiff R. Growth factor receptor cross-talk with estrogen
receptor as a mechanism for tamoxifen resistance in breast cancer. Breast
(Edinburgh, Scotland). 2003;12:362–7.
14. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK. Cross-talk
between estrogen receptor and growth factor pathways as a molecular target
for overcoming endocrine resistance. Clin Cancer Res. 2004;10:331S–6S.
15. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R.
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu
cross-talk in ER/HER2-positive breast cancer. JNCI J Natl Cancer Inst. 2004;96:
926–35.
16. Arpino G, Wiechmann L, Osborne CK, Schiff R. Crosstalk between the
estrogen receptor and the HER tyrosine kinase receptor family: molecular
mechanism and clinical implications for endocrine therapy resistance.
Endocr Rev. 2008;29:217–33.
17. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer.
Annu Rev Med. 2011;62:233–47.
18. Mehta A, Tripathy D. Co-targeting estrogen receptor and HER2 pathways in
breast cancer. Breast (Edinburgh, Scotland). 2014;23:2–9.
19. Clarke R, Tyson JJ, Dixon JM. Endocrine resistance in breast cancer—an
overview and update. Mol Cell Endocrinol. 2015;418(Pt 3):220–34.
20. Brufsky AM. Long-term management of patients with hormone receptor-
positive metastatic breast cancer: concepts for sequential and combination
endocrine-based therapies. Cancer Treat Rev. 2017;59:22–32.
21. Sassen A, Rochon J, Wild P, Hartmann A, Hofstaedter F, Schwarz S, Brockhoff
G. Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast
cancer patients. Breast Cancer Res. 2008;10:R2.
22. Sassen A, Diermeier-Daucher S, Sieben M, Ortmann O, Hofstaedter F,
Schwarz S, Brockhoff G. Presence of HER4 associates with increased
sensitivity to herceptin in patients with metastatic breast cancer. Breast
Cancer Res. 2009;11:R50.
23. Machleidt A, Buchholz S, Diermeier-Daucher S, Zeman F, Ortmann O, Brockhoff
G. The prognostic value of Her4 receptor isoform expression in triple-negative
and Her2 positive breast cancer patients. BMC Cancer. 2013;13:437.
24. Lodge AJ, Anderson JJ, Gullick WJ, Haugk B, Leonard RCF, Angus B. Type 1
growth factor receptor expression in node positive breast cancer: adverse
prognostic significance of c-erbB-4. J Clin Pathol. 2003;56:300–4.
25. Portier BP, Minca EC, Wang Z, Lanigan C, Gruver AM, Downs-Kelly E, Budd
GT, Tubbs RR. HER4 expression status correlates with improved outcome in
both neoadjuvant and adjuvant trastuzumab treated invasive breast
carcinoma. Oncotarget. 2013;4:1662–72.
26. Canfield K, Li J, Wilkins OM, Morrison MM, Ung M, Wells W, Williams CR, Liby
KT, Vullhorst D, Buonanno A, Hu H, Schiff R, Cook RS, Kurokawa M. Receptor
tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in
breast cancer cells. Cell Cycle (Georgetown, Tex). 2015;14:648–55.
27. Brockhoff G, Seitz S, Weber F, Zeman F, Klinkhammer-Schalke M, Ortmann
O, Wege AK. The presence of PD-1 positive tumor infiltrating lymphocytes
in triple negative breast cancers is associated with a favorable outcome of
disease. Oncotarget. 2018;9:6201–12.
28. Junttila TT, Sundvall M, Määttä JA, Elenius K. Erbb4 and its isoforms:
selective regulation of growth factor responses by naturally occurring
receptor variants. Trends Cardiovasc Med. 2000;10:304–10.
29. Junttila TT, Sundvall M, Lundin M, Lundin J, Tanner M, Härkönen P, Joensuu
H, Isola J, Elenius K. Cleavable ErbB4 isoform in estrogen receptor-regulated
growth of breast cancer cells. Cancer Res. 2005;65:1384–93.
30. Brockhoff G, Heckel B, Schmidt-Bruecken E, Plander M, Hofstaedter F,
Vollmann A, Diermeier S. Differential impact of cetuximab, pertuzumab and
trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation. Cell
Prolif. 2007;40:488–507.
31. Diermeier-Daucher S, Breindl S, Buchholz S, Ortmann O, Brockhoff G.
Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast
cancer cell lines in the presence of ErbB receptor-specific growth factors.
Cytometry A. 2011;79:684–93.
32. Rokicki J, Das PM, Giltnane JM, Wansbury O, Rimm DL, Howard BA, Jones FE.
The ERalpha coactivator, HER4/4ICD, regulates progesterone receptor
expression in normal and malignant breast epithelium. Mol Cancer. 2010;9:150.
33. Jones FE. HER4 intracellular domain (4ICD) activity in the developing mammary
gland and breast cancer. J Mammary Gland Biol Neoplasia. 2008;13:247–58.
34. Hollmén M, Liu P, Kurppa K, Wildiers H, Reinvall I, Vandorpe T, Smeets A,
Deraedt K, Vahlberg T, Joensuu H, Leahy DJ, Schöffski P, Elenius K.
Proteolytic processing of ErbB4 in breast cancer. PLoS One. 2012;7:e39413.
35. Komuro A, Nagai M, Navin NE, Sudol M. WW domain-containing protein
YAP associates with ErbB-4 and acts as a co-transcriptional activator for the
carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J Biol
Chem. 2003;278:33334–41.
36. Naresh A, Thor AD, Edgerton SM, Torkko KC, Kumar R, Jones FE. The HER4/
4ICD estrogen receptor coactivator and BH3-only protein is an effector of
tamoxifen-induced apoptosis. Cancer Res. 2008;68:6387–95.
37. Mohd Nafi SN, Generali D, Kramer-Marek G, Gijsen M, Strina C, Cappelletti M,
Andreis D, Haider S, Li J-L, Bridges E, Capala J, Ioannis R, Harris AL, Kong A.
Nuclear HER4 mediates acquired resistance to trastuzumab and is
associated with poor outcome in HER2 positive breast cancer. Oncotarget.
2014;5:5934–49.
38. Thor AD, Edgerton SM, Jones FE. Subcellular localization of the HER4
intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast
cancer patients. Am J Pathol. 2009;175:1802–9.
39. Muraoka-Cook RS, Sandahl MA, Strunk KE, Miraglia LC, Husted C, Hunter DM,
Elenius K, Chodosh LA, Earp HS. ErbB4 splice variants Cyt1 and Cyt2 differ
by 16 amino acids and exert opposing effects on the mammary epithelium
in vivo. Mol Cell Biol. 2009;29:4935–48.
40. Elenius K, Corfas G, Paul S, Choi CJ, Rio C, Plowman GD, Klagsbrun M. A
novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific
tissue distribution and differential processing in response to phorbol ester. J
Biol Chem. 1997;272:26761–8.
41. Veikkolainen V, Vaparanta K, Halkilahti K, Iljin K, Sundvall M, Elenius K.
Function of ERBB4 is determined by alternative splicing. Cell Cycle
(Georgetown, Tex.). 2011;10:2647–57.
42. Guler G, Iliopoulos D, Guler N, Himmetoglu C, Hayran M, Huebner K. Wwox
and Ap2gamma expression levels predict tamoxifen response. Clin Cancer
Res. 2007;13:6115–21.
43. Miller WR. Aromatase and the breast: regulation and clinical aspects.
Maturitas. 2006;54:335–41.
44. Shimizu H, Ross RK, Bernstein L, Pike MC, Henderson BE. Serum oestrogen
levels in postmenopausal women: comparison of American whites and
Japanese in Japan. Br J Cancer. 1990;62:451–3.
45. Pasqualini JR, Chetrite G, Blacker C, Feinstein MC, Delalonde L, Talbi M,
Maloche C. Concentrations of estrone, estradiol, and estrone sulfate and
evaluation of sulfatase and aromatase activities in pre- and postmenopausal
breast cancer patients. J Clin Endocrinol Metab. 1996;81:1460–4.
46. van Landeghem AA, Poortman J, Nabuurs M, Thijssen JH. Endogenous
concentration and subcellular distribution of estrogens in normal and
malignant human breast tissue. Cancer Res. 1985;45:2900–6.
47. Blankenstein MA, Maitimu-Smeele I, Donker GH, Daroszewski J, Milewicz A,
Thijssen JH. On the significance of in situ production of oestrogens in
human breast cancer tissue. J Steroid Biochem Mol Biol. 1992;41:891–6.
48. Lønning PE, Helle H, Duong NK, Ekse D, Aas T, Geisler J. Tissue estradiol is
selectively elevated in receptor positive breast cancers while tumour
estrone is reduced independent of receptor status. J Steroid Biochem Mol
Biol. 2009;117:31–41.
49. Hollmén M, Määttä JA, Bald L, Sliwkowski MX, Elenius K. Suppression of
breast cancer cell growth by a monoclonal antibody targeting cleavable
ErbB4 isoforms. Oncogene. 2009;28:1309–19.
50. Yoshioka T, Shien K, Namba K, Torigoe H, Sato H, Tomida S, Yamamoto H,
Asano H, Soh J, Tsukuda K, Nagasaka T, Fujiwara T, Toyooka S. Antitumor
activity of pan-HER inhibitors in HER2-positive gastric cancer. Cancer Sci.
2018. https://doi.org/10.1111/cas.13546 .
Wege et al. Breast Cancer Research          (2018) 20:139 Page 14 of 15
51. Zhang X, Munster PN. New protein kinase inhibitors in breast cancer:
afatinib and neratinib. Expert Opin Pharmacother. 2014;15:1277–88.
52. Vollmann-Zwerenz A, Diermeier-Daucher S, Wege AK, Sassen A, Schmidt-
Brücken E, Hofstaedter F, Ortmann O, Nauwelaers F, Brockhoff G.
Multichromatic phenotyping of HER receptor coexpression in breast tumor
tissue samples using flow cytometry—possibilities and limitations.
Cytometry A. 2010;77:387–98.
53. Nuciforo P, Radosevic-Robin N, Ng T, Scaltriti M. Quantification of HER family
receptors in breast cancer. Breast Cancer Res. 2015;17:53.
Wege et al. Breast Cancer Research          (2018) 20:139 Page 15 of 15
